Syngene International announced its fiscal year 2026 results, reporting a 3% increase in full-year revenue to Rs. 3,739 Cr. Despite a challenging year for the biotech sector, the company maintained steady operations and invested in high-growth modalities. The board has recommended a final dividend of Rs. 1.25 per share, reflecting confidence in the company’s long-term growth and strong balance sheet, with Rs. 521 Cr in net cash generated during the year.
Financial Performance Overview
For the fiscal year ending March 31, 2026, Syngene recorded revenue from operations of Rs. 3,739 Cr, representing a 3% year-on-year growth. The fourth quarter saw a revenue of Rs. 1,037 Cr, up 2% compared to the same period in the previous year. Operating EBITDA margins for the full year stood at 25%, while the Profit After Tax (before exceptional items) reached Rs. 380 Cr.
Strategic Investments and Operations
Syngene continued its strategic focus on expanding its capabilities in high-growth areas, particularly in Antibody-Drug Conjugates (ADCs). The company successfully launched its ADC discovery laboratory, which supports high-throughput experimentation. Additionally, Syngene strengthened its regulatory footprint, completing 85 audits throughout the year and achieving GCP-NABL accreditation, further validating its commitment to global quality standards.
Leadership Transitions
The company announced significant leadership changes to drive its next phase of growth. Ms. Kiran Mazumdar-Shaw has transitioned to the role of Executive Chairperson, effective April 1, 2026. Furthermore, Mr. Siddharth Mittal has been appointed as the new Managing Director and Chief Executive Officer, effective July 1, 2026, succeeding Peter Bains. These changes are designed to align with Syngene’s long-term expansion goals and commitment to delivering scientific excellence.
Sustainability and Future Outlook
Syngene’s commitment to sustainability was recognized by its inclusion in the S&P Global Sustainability Yearbook 2026, where it ranked among the top 10 life sciences companies globally. Looking ahead, the company remains focused on building new business lines and leveraging AI and digital capabilities to enhance productivity and value creation for its global client base of over 400 customers.
Source: BSE
